Susquehanna International Group
CLRB icon

Susquehanna International Group’s Cellectar Biosciences CLRB Stock Holding History

Susquehanna International Group’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-820
Closed -$61.5K – 12094
2024
Q2 		$61.5K Buy
820
+240
+41% +$23K ﹤0.01% 11323
2024
Q1 		$69.3K Buy
+580
New +$62.9K ﹤0.01% 11416

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group's CLRB Position: Q1 2026 in Review

Susquehanna International Group sold out of Cellectar Biosciences (CLRB) in Q1 2026, closing a stake of 12,204 shares — an estimated $36K sold.

Susquehanna International Group first reported a position in CLRB in Q4 2016 and held it in 9 quarters. The position peaked at $678K in Q4 2017. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • Susquehanna International Group reported no remaining Cellectar Biosciences position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 12,204 Cellectar Biosciences shares in Q1 2026, an estimated $36K.
  • Susquehanna International Group first reported a position in Cellectar Biosciences in Q4 2016 and held it in 9 quarters.
  • Susquehanna International Group's Cellectar Biosciences position peaked at $678K in Q4 2017.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.